Market Outlook: A One-Time Edit Reshapes the HAE Playbook A single gene edit cutting hereditary angioedema attacks by 87% is forcing the HAE market to rethink risk, price, and care delivery all at once, and the clock on first-in-class approval has started. The headline efficacy for Intellia
Volunteers gave blood, scans, and the secrets of their DNA to help science cure disease, yet the same data traveled across borders, landed on an e-commerce site, and revealed how easily controlled access can turn into copyable stock that outlives promises, policies, and platforms. The UK Biobank
A quiet revolution gathered force each time a clinician asked a deceptively simple question with life-and-death stakes: could the deadliest radiation be guided to the tumor’s heart and fade before it harms everything else nearby, leaving behind a crater of damage in cancer cells and a smaller b
Faisal Zain has spent years on factory floors and in clinical back rooms turning medical technology from schematics into approved devices. That end-to-end perspective—how ideas survive contact with regulators, providers, and patients—informs his work with Treehub’s cohort-based residencies in Los Al
A newborn infant resting in a quiet nursery currently possesses a world of silent potential that was once destined to remain forever beyond the reach of biological intervention. For decades, the standard of care for congenital deafness has been the cochlear implant, a marvel of engineering that
The recent regulatory clearance of a novel therapeutic option marks a definitive departure from the historical reliance on aggressive multi-drug cocktails for the lifelong management of human immunodeficiency virus. Merck’s newly approved medication, Idvynso, represents a strategic evolution in c
